← brief for 2026-08-10 · Slowing decline

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Trial No results yet Not peer reviewed

Key takeaways

This trial tests a new drug, BI 690517, added to empagliflozin in adults with chronic kidney disease who are at risk of getting worse. People with or without diabetes can join, including those already on standard kidney drugs. It is enrolling now, so there are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: Apogee Clinical Research · Southwest Kidney Institute · National Heart Institute · Florida Kidney Physicians LLC · Total Research Group, LLC · Emory University School of Medicine

Source

Trial registration · ClinicalTrials.gov — CKD recruiting · 2026-08-10
https://clinicaltrials.gov/study/NCT06531824